Can Rituximab Cause Psychosis?
Rituximab does not directly cause psychosis as a primary adverse effect; rather, it has been used successfully to treat psychiatric manifestations including psychosis in refractory cases of systemic lupus erythematosus (SLE). However, rituximab can cause serious neurological complications including posterior reversible encephalopathy syndrome (PRES), which may present with altered mental status and hallucinations that could be mistaken for psychosis 1, 2, 3.
Understanding the Clinical Context
The relationship between rituximab and psychiatric symptoms requires careful distinction between several scenarios:
Rituximab as Treatment for Psychosis
In SLE patients with lupus psychosis (characterized by delusions or hallucinations), rituximab has demonstrated rapid and significant improvement of psychiatric manifestations in refractory cases 4. This represents therapeutic benefit, not causation of psychosis.
Rituximab-Associated Neurological Complications
The FDA label and clinical evidence identify several serious neurological adverse reactions 1:
Posterior Reversible Encephalopathy Syndrome (PRES): This is the most relevant neurological complication that can mimic psychosis. PRES presents with altered mental status, visual disturbances, hallucinations, seizures, and cortical blindness 2, 3. Brain MRI shows characteristic symmetric hyperintensities in occipital and parietal lobes on T2-weighted sequences.
Onset timing: PRES can occur after the first dose but has been reported after subsequent cycles as well 3.
Reversibility: Symptoms typically resolve within days to weeks after rituximab discontinuation, with complete neurological recovery 2.
Distinguishing PRES from Primary Psychosis
Key clinical features that suggest PRES rather than primary psychosis:
- Acute onset of visual symptoms (cortical blindness, visual field defects)
- Seizures or hyperreflexia
- Severe headaches
- Hypertension
- Characteristic MRI findings with vasogenic edema in posterior brain regions
Pharmacovigilance Data
A comprehensive 2026 pharmacovigilance study analyzing multiple adverse event databases identified psychiatric adverse reactions associated with rituximab, including anxiety (ROR = 2.08), reading disorder, and attention deficit hyperactivity disorder 5. However, these signals emerged primarily in the context of immune-mediated kidney diseases with extended therapy (>720 days), and the study did not specifically identify psychosis as a prominent signal.
Clinical Management Algorithm
If psychiatric symptoms develop during rituximab therapy:
Immediate assessment for PRES:
Consider alternative causes:
- Corticosteroid-induced psychiatric disease (occurs in 10% of patients on prednisone ≥1 mg/kg, manifests primarily as mood disorder rather than psychosis) 4
- Underlying disease activity (e.g., lupus psychosis if treating SLE)
- Infections or metabolic disturbances
- Other medications
Supportive management if PRES:
- Blood pressure control
- Antiepileptic drugs if seizures present
- Symptoms typically resolve within days of rituximab cessation 2
Important Caveats
Do not confuse treatment of psychosis with causation: The evidence shows rituximab treats psychiatric manifestations in SLE, not that it causes them 4.
PRES is rare but serious: While uncommon, PRES can be life-threatening if not recognized and managed promptly 2, 3.
Infusion reactions are common but distinct: Up to 77% of patients may experience infusion-related reactions during first exposure, but these typically manifest as constitutional symptoms, not psychiatric symptoms 6.
Long-term surveillance: Extended rituximab therapy (>720 days) may be associated with increased psychiatric adverse reactions, warranting vigilant monitoring 5.
The bottom line: Rituximab does not cause primary psychosis, but can cause PRES which presents with altered mental status and hallucinations that require immediate recognition and drug discontinuation.